Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Novel Te-Ethosomes-loaded Thermosensitive Gel for Enhanced Transdermal Delivery and Melasma Therapy.

Journal of drug targeting·2026

Same author

Analysis of clinical characteristics of 38 patients with dextrocardia: An observational study.

Medicine·2026

Same author

Advanced Degradation and Remediation Strategies for Per- and Polyfluoroalkyl Substances (PFASs): Challenges and Future Perspectives.

Toxics·2026

Same author

HDAC2-mediated H3K27ac Governs ZFP42 transcription and autophagy in granulosa cells of pigs.

Life sciences·2026

Same author

The predictive value of contrast-enhanced CT characteristics combined with composite inflammatory markers for lymph node metastasis in T1 colorectal cancer.

International journal of colorectal disease·2026

Same author

Half-Sandwich Ir(III) and Ru(II) Complexes Featuring a Coumarin-Based Chelating Core for Mitochondrial-Targeted Anticancer Activity.

Inorganic chemistry·2026

Search research articles

Related Experiment Video

Updated: Jun 25, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Imatinib-induced ulcerative colitis.

Zengqing Ma¹, Jianguo Zhao¹, Susu Li¹

¹Department of Pharmacy, Nanjing Gaochun People's Hospital, Nanjing, China.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners

|May 21, 2024

Summary

This summary is machine-generated.

Imatinib, a cancer drug, can rarely cause ulcerative colitis (UC). This case highlights the need to consider UC in GIST patients experiencing diarrhea and bloody stools during imatinib treatment.

Keywords:

Imatinib adverse drug reaction gastrointestinal stromal tumor ulcerative colitis

More Related Videos

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Published on: June 2, 2023

Intestinal Epithelial Regeneration in Response to Ionizing Irradiation

Intestinal Epithelial Regeneration in Response to Ionizing Irradiation

Published on: July 27, 2022

Related Experiment Videos

Last Updated: Jun 25, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Published on: June 2, 2023

Intestinal Epithelial Regeneration in Response to Ionizing Irradiation

Intestinal Epithelial Regeneration in Response to Ionizing Irradiation

Published on: July 27, 2022

Area of Science:

Gastroenterology
Oncology
Pharmacology

Background:

Imatinib is a standard first-line therapy for KIT-mutated gastrointestinal stromal tumors (GIST).
Common imatinib side effects include nausea, vomiting, diarrhea, dyspepsia, and abdominal pain.
Imatinib-induced ulcerative colitis (UC) is a rare but significant adverse event.

Observation:

A 56-year-old male patient developed UC after 5 years of imatinib therapy for GIST.
Symptoms included diarrhea and bloody stools, which improved upon imatinib discontinuation.
Re-initiation of imatinib led to symptom recurrence, suggesting a causal link.

Findings:

This case provides objective evidence of imatinib-induced UC.
The patient's adverse event resolved with imatinib withdrawal and supportive care.
The temporal relationship and recurrence upon re-challenge strongly implicate imatinib.

Implications:

Clinicians should maintain a high index of suspicion for UC in GIST patients on imatinib presenting with gastrointestinal bleeding or severe diarrhea.
Early recognition and management of imatinib-induced UC can prevent complications and guide treatment decisions.
This case underscores the importance of monitoring for rare adverse drug reactions during long-term cancer therapy.